Trial Profile

A Single-arm Phase Ib/II Study of the Combination of Lenvatinib and Eribulin in Advanced Adipocytic Sarcoma and Leiomyosarcoma (LEADER Study)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eribulin (Primary) ; Lenvatinib (Primary)
Indications Leiomyosarcoma; Liposarcoma
Focus Adverse reactions; Therapeutic Use
Acronyms LEADER

Most Recent Events

25 Nov 2024 Planned End Date changed from 30 Jun 2022 to 30 Dec 2024.
27 Dec 2022 Planned End Date changed from 1 Dec 2022 to 30 Jun 2022.
13 Sep 2022 Results by deriving samples from LEADER study and assessing immune and vascular biomarkers associated with efficacy and mechanism of actions of the combination of lenvatinib and eribulin in leiomyosarcoma and liposarcoma , presented at the 47th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com